TITLE

Disease Dilemma

AUTHOR(S)
Huff, Charlotte
PUB. DATE
April 2005
SOURCE
H&HN: Hospitals & Health Networks;Apr2005, Vol. 79 Issue 4, p24
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Focuses on the results of several studies on the cost-savings benefits of disease management programs to patients and hospitals in the U.S. Ways to achieve the benefits of the concept recommended by doctor Autumn Dawn Galbreath; Strategies for disease management programs; Scope of the 2003 Medicare reform law.
ACCESSION #
16741564

 

Related Articles

  • A solution on the brink. Sloane, Todd // Modern Healthcare;1/30/2006, Vol. 36 Issue 5, p22 

    The article reflects on the cost-effectiveness of managing high-cost patient populations in the U.S. It cites an example of the troubling and counterintuitive nature of the mixed results of research and business track records regarding disease management. It argues on the need for evidence-based...

  • Demand management may help stem costs. Montrose, Gary // Health Management Technology;Feb1995, Vol. 16 Issue 2, p18 

    Reports on the emerging science of `demand management' and its application to healthcare systems. Reduction of the need for and use of costly,clinically unnecessary medical services and arbitrary managed-care observations without compromising health as demand management goal; Discussion of...

  • Costs and consequences of enhanced primary care for depression: systematic review of randomised economic evaluations. Gilbody, Simon; Bower, Peter; Whitty, Paula // British Journal of Psychiatry;Oct2006, Vol. 189, p297 

    Background: A number of enhancement strategies have been proposed to improve the quality and outcome of care for depression in primary care settings. Decision-makers are likely to need to know whether these interventions are cost-effective in routine primary care...

  • Paying for Disease Management. Levy, Phillip; Nocerini, Robert; Grazier, Kyle // Disease Management;Aug2007, Vol. 10 Issue 4, p235 

    Disease Management (DM) first appeared in the United States in the early 1990s. Since then its incorporation into health plans has increased dramatically, yet proof of its effectiveness in terms of quality improvement and cost reduction remains to be seen. The following review provides an...

  • Employers focus on cost control for health savings. Prince, Michael // Business Insurance;7/7/2003, Vol. 37 Issue 27, p20 

    To rein in rising health care costs, more employers are turning to where the big expenses are. More than in past years, employers in 2003 are adding disease management programs to their toolbox of cost-control methods. Implementing these programs, in addition to the well-used strategy of...

  • Therapeutic Specificity in Disease Management Evaluation. MacStravic, Scott // Disease Management;Feb2008, Vol. 11 Issue 1, p7 

    The author reflects on the therapeutic specificity in disease management (DM) evaluation. He notes that there must be a clear connection between the cause of DM and any changes claimed as effects if any positive changes are detected after a DM intervention. He also added that the attributed...

  • Between A Rock And A Hard Place: Understanding The Employer Mind-Set. Galvin, Robert S.; Delbanco, Suzanne // Health Affairs;Nov/Dec2006, Vol. 25 Issue 6, p1548 

    Large and mid-size employers are ‘between a rock and hard place’ when it comes to health benefits: They are both unable to manage their health care costs effectively or simply get out of offering these benefits entirely. Although there is considerable diversity in how employers...

  • Cost-Effectiveness Information: Yes, It's Important, but Keep It Separate, Please! Wilensky, Gail R. // Annals of Internal Medicine;6/17/2008, Vol. 148 Issue 12, p967 

    The author comments on the recommendation of American College of Physicians (ACP) to the U.S. to invest in a national entity that would generate information on clinical comparative effectiveness and to include the cost-effectiveness analysis on its scope. She argues that the cost-effectiveness...

  • Expensive Cancer Drugs With Modest Benefit Ignite Debate Over Solutions. Sinha, Gunjan // JNCI: Journal of the National Cancer Institute;10/1/2008, Vol. 100 Issue 19, p1347 

    The article focuses on highly priced cancer drugs with low benefits in the U.S. Justification on high prices charged on drugs medication with unproven benefits has been the issue in the healthcare sector. These caused a long debate on how American patients can use the health care system under a...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics